Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach